Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Schrödinger’s Initial-Stage Cancer Study Gains FDA Clearance
Schrödinger Inc. (NASDAQ: SDGR) announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for the drug candidate SGR-1505 in patients with relapsed or refractory B-cell lymphoma.
Schrödinger Announces FDA Clearance Of Investigational New Drug Application For SGR-1505, A MALT1 Inhibitor
Phase 1 Clinical Trial in Patients with Advanced B-Cell Malignancies Expected to Begin in the Second Half of 2022
NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform
Morgan Stanley Maintains Equal-Weight on Schrodinger, Lowers Price Target to $34
Morgan Stanley maintains Schrodinger (NASDAQ:SDGR) with a Equal-Weight and lowers the price target from $35 to $34.
Recap: Schrodinger Q1 Earnings
Schrodinger (NASDAQ:SDGR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Schrodinger beat estimated earnings by 7.69%, reporting an EPS of $-0.48 versus an estimate of $-0.52.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
AI Pharma Startup METiS Raises $150 Million. IPO In Sight?
Key takeaways:
METiS Pharmaceuticals has completed five funding rounds since its establishment in January 2020, including the latest two worth $150 million
The company was incubated by AI pharmaceutical unicorn XtaiPl, whose most recent valuation exceeded $2.05 billion
By Molly Wen
Schrödinger Reports New Preclinical Data Supporting Advancement Of Its Wee1 Inhibitor Program At American Association Of Cancer Research 2022 Annual Meeting
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today presented new preclinical data from its Wee1 inhibitor program in a
